Second monotherapy in childhood absence epilepsy

Childhood Absence Epilepsy Study Group

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To determine optimal second monotherapy for children with childhood absence epilepsy (CAE) experiencing initial treatment failure. Methods: Children with CAE experiencing treatment failure during the double-blind phase of a randomized controlled trial comparing ethosuximide, valproic acid, and lamotrigine were randomized to open-label second monotherapy with one of the 2 other study therapies. Primary study outcome was freedom from failure proportion at week 16-20 and month 12 visits after randomization. Secondary study outcome was percentage of participants experiencing attentional dysfunction at these visits. Results: A total of 208 children were enrolled, randomized, and received second therapy. At both week 16-20 visit and month 12 visit, ethosuximide's (63%, 57%) and valproic acid's (65%, 49%) freedom from failure proportions were similar to each other and higher than lamotrigine's (45%, 36%, p = 0.051 and p = 0.062). At both time points, ethosuximide and valproic acid had superior seizure control compared to lamotrigine (p < 0.0001). At both the week 16-20 and month 12 visits, attentional dysfunction was numerically more common with valproic acid than with ethosuximide or lamotrigine. For each medication, second monotherapy freedom from failure proportions demonstrated noninferiority to initial monotherapy freedom from failure proportions. Conclusions: As second monotherapy, ethosuximide and valproic acid, demonstrated higher freedom from failure proportions and greater efficacy than lamotrigine; valproic acid was associated with more attentional dysfunction. Ethosuximide is the optimal second monotherapy for children with CAE not responding to initial therapy with other medications. ClinicalTrials.gov identifier: NCT00088452. Classification of evidence: This study provides Class III evidence that for children with CAE experiencing initial treatment failure, second monotherapy with ethosuximide or valproic acid is superior to lamotrigine.

Original languageEnglish (US)
Pages (from-to)182-190
Number of pages9
JournalNeurology
Volume88
Issue number2
DOIs
StatePublished - Jan 10 2017

Fingerprint

Ethosuximide
Absence Epilepsy
Valproic Acid
Treatment Failure
Outcome Assessment (Health Care)
Random Allocation
lamotrigine
Seizures
Therapeutics
Randomized Controlled Trials

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Second monotherapy in childhood absence epilepsy. / Childhood Absence Epilepsy Study Group.

In: Neurology, Vol. 88, No. 2, 10.01.2017, p. 182-190.

Research output: Contribution to journalArticle

Childhood Absence Epilepsy Study Group 2017, 'Second monotherapy in childhood absence epilepsy', Neurology, vol. 88, no. 2, pp. 182-190. https://doi.org/10.1212/WNL.0000000000003480
Childhood Absence Epilepsy Study Group. Second monotherapy in childhood absence epilepsy. Neurology. 2017 Jan 10;88(2):182-190. https://doi.org/10.1212/WNL.0000000000003480
Childhood Absence Epilepsy Study Group. / Second monotherapy in childhood absence epilepsy. In: Neurology. 2017 ; Vol. 88, No. 2. pp. 182-190.
@article{3ad45110919143cd9e941b7dcc5075d0,
title = "Second monotherapy in childhood absence epilepsy",
abstract = "Objective: To determine optimal second monotherapy for children with childhood absence epilepsy (CAE) experiencing initial treatment failure. Methods: Children with CAE experiencing treatment failure during the double-blind phase of a randomized controlled trial comparing ethosuximide, valproic acid, and lamotrigine were randomized to open-label second monotherapy with one of the 2 other study therapies. Primary study outcome was freedom from failure proportion at week 16-20 and month 12 visits after randomization. Secondary study outcome was percentage of participants experiencing attentional dysfunction at these visits. Results: A total of 208 children were enrolled, randomized, and received second therapy. At both week 16-20 visit and month 12 visit, ethosuximide's (63{\%}, 57{\%}) and valproic acid's (65{\%}, 49{\%}) freedom from failure proportions were similar to each other and higher than lamotrigine's (45{\%}, 36{\%}, p = 0.051 and p = 0.062). At both time points, ethosuximide and valproic acid had superior seizure control compared to lamotrigine (p < 0.0001). At both the week 16-20 and month 12 visits, attentional dysfunction was numerically more common with valproic acid than with ethosuximide or lamotrigine. For each medication, second monotherapy freedom from failure proportions demonstrated noninferiority to initial monotherapy freedom from failure proportions. Conclusions: As second monotherapy, ethosuximide and valproic acid, demonstrated higher freedom from failure proportions and greater efficacy than lamotrigine; valproic acid was associated with more attentional dysfunction. Ethosuximide is the optimal second monotherapy for children with CAE not responding to initial therapy with other medications. ClinicalTrials.gov identifier: NCT00088452. Classification of evidence: This study provides Class III evidence that for children with CAE experiencing initial treatment failure, second monotherapy with ethosuximide or valproic acid is superior to lamotrigine.",
author = "{Childhood Absence Epilepsy Study Group} and Avital Cnaan and Shlomo Shinnar and Ravindra Arya and Adamson, {Peter C.} and Clark, {Peggy O.} and Dennis Dlugos and Hirtz, {Deborah G.} and David Masur and Glauser, {Tracy A.}",
year = "2017",
month = "1",
day = "10",
doi = "10.1212/WNL.0000000000003480",
language = "English (US)",
volume = "88",
pages = "182--190",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Second monotherapy in childhood absence epilepsy

AU - Childhood Absence Epilepsy Study Group

AU - Cnaan, Avital

AU - Shinnar, Shlomo

AU - Arya, Ravindra

AU - Adamson, Peter C.

AU - Clark, Peggy O.

AU - Dlugos, Dennis

AU - Hirtz, Deborah G.

AU - Masur, David

AU - Glauser, Tracy A.

PY - 2017/1/10

Y1 - 2017/1/10

N2 - Objective: To determine optimal second monotherapy for children with childhood absence epilepsy (CAE) experiencing initial treatment failure. Methods: Children with CAE experiencing treatment failure during the double-blind phase of a randomized controlled trial comparing ethosuximide, valproic acid, and lamotrigine were randomized to open-label second monotherapy with one of the 2 other study therapies. Primary study outcome was freedom from failure proportion at week 16-20 and month 12 visits after randomization. Secondary study outcome was percentage of participants experiencing attentional dysfunction at these visits. Results: A total of 208 children were enrolled, randomized, and received second therapy. At both week 16-20 visit and month 12 visit, ethosuximide's (63%, 57%) and valproic acid's (65%, 49%) freedom from failure proportions were similar to each other and higher than lamotrigine's (45%, 36%, p = 0.051 and p = 0.062). At both time points, ethosuximide and valproic acid had superior seizure control compared to lamotrigine (p < 0.0001). At both the week 16-20 and month 12 visits, attentional dysfunction was numerically more common with valproic acid than with ethosuximide or lamotrigine. For each medication, second monotherapy freedom from failure proportions demonstrated noninferiority to initial monotherapy freedom from failure proportions. Conclusions: As second monotherapy, ethosuximide and valproic acid, demonstrated higher freedom from failure proportions and greater efficacy than lamotrigine; valproic acid was associated with more attentional dysfunction. Ethosuximide is the optimal second monotherapy for children with CAE not responding to initial therapy with other medications. ClinicalTrials.gov identifier: NCT00088452. Classification of evidence: This study provides Class III evidence that for children with CAE experiencing initial treatment failure, second monotherapy with ethosuximide or valproic acid is superior to lamotrigine.

AB - Objective: To determine optimal second monotherapy for children with childhood absence epilepsy (CAE) experiencing initial treatment failure. Methods: Children with CAE experiencing treatment failure during the double-blind phase of a randomized controlled trial comparing ethosuximide, valproic acid, and lamotrigine were randomized to open-label second monotherapy with one of the 2 other study therapies. Primary study outcome was freedom from failure proportion at week 16-20 and month 12 visits after randomization. Secondary study outcome was percentage of participants experiencing attentional dysfunction at these visits. Results: A total of 208 children were enrolled, randomized, and received second therapy. At both week 16-20 visit and month 12 visit, ethosuximide's (63%, 57%) and valproic acid's (65%, 49%) freedom from failure proportions were similar to each other and higher than lamotrigine's (45%, 36%, p = 0.051 and p = 0.062). At both time points, ethosuximide and valproic acid had superior seizure control compared to lamotrigine (p < 0.0001). At both the week 16-20 and month 12 visits, attentional dysfunction was numerically more common with valproic acid than with ethosuximide or lamotrigine. For each medication, second monotherapy freedom from failure proportions demonstrated noninferiority to initial monotherapy freedom from failure proportions. Conclusions: As second monotherapy, ethosuximide and valproic acid, demonstrated higher freedom from failure proportions and greater efficacy than lamotrigine; valproic acid was associated with more attentional dysfunction. Ethosuximide is the optimal second monotherapy for children with CAE not responding to initial therapy with other medications. ClinicalTrials.gov identifier: NCT00088452. Classification of evidence: This study provides Class III evidence that for children with CAE experiencing initial treatment failure, second monotherapy with ethosuximide or valproic acid is superior to lamotrigine.

UR - http://www.scopus.com/inward/record.url?scp=85009083351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009083351&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003480

DO - 10.1212/WNL.0000000000003480

M3 - Article

VL - 88

SP - 182

EP - 190

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -